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ConformalAbstract Purpose: To analyze the clinical outcome of primary orbital lymphoma (POL) patients
treated with a combined modality approach with local radiotherapy after induction chemotherapy.
Methodology: We retrospectively retrieved demographic, treatment and outcome data of patients
treated for POL from 2000 to 2010. The charts were reviewed and the data were tabulated in a pre-
designed pro-forma.
Results: 23 patients of POL were found evaluable. Median age was 55 years (range 24–70 years).
Of 23 patients, 15 were male and 8 female, making the male:female ratio approximately 1.9:1.
Patients were thoroughly evaluated and staged. All but one patient received multi agent chemother-
apy. Radiotherapy was delivered for all cases. Radiation was delivered by 3DCRT technique.
Median dose of radiation was 45 Gy (range 20–45 Gy). Median follow up was 26.8 months.
None of the patients had any evidence of local failure or systemic progression.
Conclusion: A combined modality therapy with a combination of CHOP/COP based chemother-
apy and moderate dose of radiotherapy imparts excellent long term local and systemic disease
control.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Primary orbital lymphoma (POL) is an uncommon extra nodal
lymphoma, accounting for 8% of all extra nodal NHL and 1%
of all NHL [1,2]. It makes up 10% of all orbital tumors [3].Maltoma has been reported to be the commonest type of
NHL in POL. However, diffuse large B cell lymphoma
(DLBCL) and marginal zone lymphoma (MZL) have also
been reported in a different series [4]. POL has been reported
to be a slow growing tumor and mostly remains conﬁned to
the orbit only. However, neglected cases may erode the bony
barrier and spread to the adjacent organs. Over the years a
moderate dose of radiation has remained the most effective
form of therapy for such tumors with excellent disease control
[5,6]. The role of chemotherapy and antibiotics has evolved
over the past decade [6]. The introduction of multi agent
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new standard and expected to improve survival further.
Here, in this report we intend to present the treatment outcome
of POL patients treated with a combined approach of radio-
therapy and chemotherapy.Methodology
Patients
We retrieved the demographic and treatment data of patients
treated for POL from 2000–2010. The charts were reviewed
and the demographic, treatment and outcome data were
retrieved using a predesigned pro-forma.
Pretreatment workup
All patients were evaluated by a team of radiation and medical
oncologist in our multidisciplinary clinic. A contrast enhanced
computed tomography (CECT) scan of the head, face and
neck, thorax and abdomen was advised. Bone marrow aspira-
tion, touch preparation and biopsy were performed to stage
these cases and conﬁrm the diagnosis of POL. A post
chemotherapy CECT scan was performed to assess response
to induction chemotherapy. A MUGA scan or 2D echocardio-
graphy was performed to assess the pretreatment left ventricu-
lar ejection fraction.
Radiation therapy
For all radiation treatments, patients were immobilized in a
thermoplastic immobilization device in the supine position
with arms by the side of the patient. For planning with confor-
mal radiation technique (three dimensional conformalFigure 1 Images depict target delineation, dosradiation therapy, 3D-CRT) planning CT scan was acquired
(with intravenous contrast) with a 3 mm slice thickness on
Philips large bore CT scanner. Treatment was delivered with
6 megavoltage photons on CL 2300 CD (Varian Medical
System, Palo Alto, California, United States). The gross tumor
volume (GTV) was deﬁned as the tumor evident on the plan-
ning CT scan. The whole orbit was considered as the clinical
target volume (CTV). The CTV volume was restricted with
respect to natural barriers such as bone. CTV was expanded
by isotropic 3–5 mm expansion for generating planning target
volume (PTV). The dose prescription ranged from 36–45 Gy at
1.8–2 Gy per fraction. Patients with a complete response (CR)
received 36 Gy and for less than a CR 45 Gy. During radio-
therapy planning the highest priority was given to achieve con-
formal dose distribution covering the PTV followed by
maximal sparing of the contralateral eye and optic apparatus
(Fig. 1).
Chemotherapy
Multi agent chemotherapy with a combination of cyclophos-
phamide, vincristine, and prednisolone (CHOP/COP) with or
without Adriamycin was prescribed for four cycles and
repeated every 3 weeks. Adriamycin was added for intermedi-
ate grade histology only.
Assessment of toxicity and follow up
Acute toxicities were assessed as per acute radiation morbidity
scoring of radiation therapy oncology group (RTOG). All
patients were assessed weekly during radiation therapy. After
the completion of treatment, patients were evaluated at
1 month and then every 3 months for ﬁrst 2 years and
6 monthly in subsequent years. Clinical examination was per-
formed at each follow up and imaging (CT/MRI) was donee color wash in a case of orbital lymphoma.
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progression.
Clinical outcome end-points and statistics
Disease free survival (DFS) for primary treatment was deﬁned
as from the start of ﬁrst treatment to the diagnosis of
recurrence. However, in the absence of any event the statistical
analysis was not possible.Results
Patients
23 patients of POL were found evaluable. Median age of the
cohort was 55 years (range 24–70 years). Of 23 patients, 15
were male and 8 female, making the male:female ratio approx-
imately 1.9:1. Proptosis (n= 23) was the commonest symptom
followed by decreased vision (n= 8), epiphora (n= 2), and
pain (n= 1). CECT scan of the face was the commonest radi-
ological investigation performed in 19 patients. The CECT
scan revealed a moderate to strongly enhancing mass in the
intra or extraconal compartment with invasion of extra ocularFigure 2 Axial CECT image showing enhancing mass in the intra o
(upper panel). MRI showing hyper intense mass on T2 weighted images
the extra ocular muscle (lower panel) (Fig. 2).muscles. Bone erosion and extension to the para nasal sinus
was noted in 2 patients. An MRI of the orbit was performed
in 8 patients. MRI revealed a hyper intense mass on T2
weighted images in the conal compartment with a variable
extent of involvement of the extra ocular muscle (Fig. 2). All
patients had unilateral involvement. The median symptom
duration was 16 months. Complete staging workup including
detailed radiological examination, bone marrow aspiration
and bone marrow biopsy was performed for all cases. 18
patients were staged as stage IAE and stage IAXE was noted
in 1 patient. 2 patients each had stage IIAE and stage IIIAE
respectively. Low grade B cell lymphoma was the commonest
histology found in 10 cases, followed by DLBCL in 7 cases.
Three patients had small cell lymphoma, 2 patients had mal-
toma and 1 patient had MZL.
Chemotherapy
All 23 but one patients received combination chemotherapy.
Eight patients received CHOP chemotherapy whereas 14
patients received COP chemotherapy. The median number of
chemotherapy cycles used was 4 (range 4 to 8). Only 5 patients
achieved a CR after the planned chemotherapy schedule. All
other patients achieved a partial response and near completer extraconal compartment with invasion of extra ocular muscles
in the conal compartment with a variable extent of involvement of
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After chemotherapy 6 (26%) patients had a complete remis-
sion, 11 (47.8%) patients had a partial response. The post
chemotherapy response was not documented for 6 cases.
Radiotherapy
Involved ﬁeld radiotherapy was used for all patients.
Radiation was delivered by 3DCRT technique. The median
dose of radiation was 45 Gy (range 20–45 Gy). The radiother-
apy course was well tolerated. The commonest toxicity noted
was grade I skin reaction noted in approximately all cases.
Conjunctivitis grade I was noted in most patients and few
had grade II reaction. There was no treatment break because
of toxicity. In all planning bolus 5 mm was placed to achieve
homogenous dose distribution. The dose to the organ at risk
for all plans was noted well below the normal tolerance limit.
Disease control
At a median follow up of 26.8 months (7.5–103.4 months)
local disease control was 100% and overall survival was
100%. None of the patients had systemic disease recurrence.
However, survival analysis was not performed because of
event.
Late toxicity
One patient was found to have keratitis in the involved eye and
managed conservatively. One patient developed cataract and
underwent cataract surgery.Discussion
Primary orbital lymphoma is uncommon and accounted for
1% of all NHL [2]. POL is found to arise from the lacrimal
gland, conjunctiva, ocular muscles and eyelid predominantly
in the 6th decade [7]. In the present series also the incidence
is more in the 6th decade and 9 patients were aged 60 years
or older. In the literature conﬂicting reports have been pub-
lished regarding male or female preponderance. However,
our experience is little different and we found POL to be twice
more frequent in male. A large majority (more than 75%) of
POL has been reported to be with low grade lymphoma and
they have an indolent clinical course [5]. Mucosa associated
lymphoma (maltoma) is the commonest histologic subtype fol-
lowed by follicular lymphoma, DLBCL, MZL, etc. On the
contrary only 2 patients had maltoma histology in the present
series. 10 patients had low grade histology including low grade
B cell NHL, maltoma [4]. The remaining 7 had DLBCL and
small cell NHL suggesting a different etiology and clinical
behavior in the present cohort. Most commonly patients pre-
sent with palpable orbital mass, followed by ptosis, proptosis
and eye irritation. In approximately 20% (10–25%) of cases
the involvement has been reported to be bilateral, however
all patients in this study population were found to have disease
localized to one eye only [8]. Chlamydia psittaci DNA has been
found in 80% cases of orbital Lymphoma [8]. Efforts have
been made to eradicate POL with doxycycline but without sub-
stantial success. Hence, the role of antibiotics in the treatmentof POL needs further standardization. However, in this cohort
antibiotics were not used. Surgery has a limited role in the
curative treatment of POL attributed to difﬁculty to achieve
complete surgery. Esik et al. reported 0% local relapse free sur-
vival after local surgery alone. Hence, surgery is not considered
curative in our institute and is not offered in any of these
patients [6].
The role of chemotherapy for POL has been questioned in
different series [6,9–11]. In low grade POL chemotherapy has
not been reported to confer any survival improvement which
may be attributable to the indolent nature of disease [12].
Another hypothesis is that the use of chemotherapy delays
the radiation therapy which has long been considered a cura-
tive for such cases. The effectiveness of radiation was estab-
lished when Esik et al. reported 42% local control with
chemotherapy in comparison to 100% local control with
radiotherapy [6]. However, despite initial good local control
40–67% high grade POL experiences systemic metastasis.
Hence, POL with high grade histology merits trial with a com-
bined modality approach. The commonly used chemotherapy
regimens COP, CHOP, or RCHOP for nodal NHL have been
extrapolated for POL also followed by local involved ﬁeld
radiotherapy [13]. Avelis et al. in a retrospective analysis
reported 98% complete response after radiotherapy alone
and 100% complete response rate after combined modality
therapy [14]. The authors reported 96% and 91% overall sur-
vival respectively at 16 years of follow up.
Radiotherapy is considered the primary curative treatment
for stage I and stage II POL. In low grade lymphoma radiation
alone and in high grade combined modality with chemother-
apy may confer long term disease control and overall survival.
The evolution of radiation technique has optimized treatment
delivery and minimizes radiation toxicity for POL. The
3DCRT and IMRT technique have enabled delivery of radia-
tion more precisely with sparing of OAR [15,16]. In the present
series all patients received conformal radiotherapy and com-
pleted the planned radiation dose without any grade III or
more toxicity. The modern techniques have made radiotherapy
more sophisticated limiting the concerns of excessive late tox-
icity also. However, the optimum radiation dose is often
debated and less data are available to comment upon the opti-
mum radiation doses. Authors in different series have advo-
cated a wide dose range (10–57 Gy) [17,18]. However, there
is a trend to use a lesser dose of radiation because of concerns
of late radiation morbidity. The dose response is quite clear in
cases of POL and the local control and the overall survival is
poor with a radiation dose of <30 Gy [17,18]. The literature
though discordant shows inclination to accept a radiation dose
of 30 Gy after CR and 40 Gy after a PR. We used 45 Gy in
conventional fractionation and the compliance was excellent
without any serious morbidity. However, the dose was reduced
to 36 Gy for low grade histology. Though small, 100% local
and systemic control with the combined modality therapy
approach should be considered the optimum treatment regi-
men. The treatment volume is however not very unclear and
the entire orbit is considered the target. In a recent review
Yadav et al. have clearly shown 33% recurrence in the ipsilat-
eral orbit after partial orbital irradiation [19]. Entire orbit was
taken as target for all cases in the present cohort. The excellent
local disease control supports the concept of whole orbital
radiation only. In the recent years the introduction of confor-
mal radiation in the form of 3DCRT and IMRT has enabled
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morbidity. Acute radiation morbidity is often very minimal,
particularly after a moderate dose treatment. However,
concerns are often expressed about the long term morbidity
and cataract remains the commonest late toxicity [5,8]. It has
been reported that the incidence of cataract formation is more
when the lens is not shielded. The incidence varies from 0–38%
with shield and 9–100% without lens shield. At present the
conformal radiation enables radiation delivery with a limited
dose to lens and other OARs. The improvement in cataract
surgery also has made this toxicity easily manageable. Late
toxicity like lacrimal gland toxicity, corneal and retinal toxicity
is very unlikely in the dose range used in POL. In the present
series grade I conjunctival congestion was the most common
toxicity noted in all patients. However, there was no treatment
interruption. We found no long term toxicity in the series;
however the follow up is limited. The study has its limitations
owing to the retrospective nature. However, POL is a relatively
uncommon disease and it seems difﬁcult to have a proper
randomized study. Homogenous radiation target volume
delineation and chemotherapy can be considered as strength
of the study.
POL is a relatively uncommon entity. The localized nature
and low to intermediate grade histology confer long term dis-
ease control. A combined modality therapy with a combina-
tion of CHOP/COP based chemotherapy and moderate dose
of radiotherapy imparts excellent long term local and systemic
disease control.Disclosures
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